Skip to content
SafetyScorer

Is Oxymorphone safe?

Oxymorphone

Oxymorphone (once sold as Opana and Opana ER) is a strong US opioid for severe pain, now sold only as generic tablets. It has the risks of oxycodone at half the dose, plus unusual sensitivity to alcohol, food and liver disease. Opana ER was withdrawn in 2017 at the FDA's request because of injection abuse.

High confidence#97 of 99 medications
Updated
Spot a mistake?

#97of 99 medications

High confidence
Agree with our score?
Brands
Opana and Opana ER (both discontinued); now generic immediate-release and extended-release tablets
Legal status
Controlled substanceA medicine or drug that the law restricts because it can be misused or cause dependence. Countries group them into schedules or classes.More in the glossary in the US; Class A in the UK
Strength
3 times oral morphine, milligram for milligram (CDC 2022 conversion factor)
Usual starting dose (US label)
Tablets 10 to 20 mg every 4 to 6 hours as needed; extended-release 5 mg every 12 hours for people new to opioids
How to take it
On an empty stomach, at least 1 hour before or 2 hours after eating
Boxed warning
Addiction, breathing problems, accidental ingestion, sedatives and alcohol, newborn withdrawal
Liver disease
Not to be used with moderate or severe liver impairment
Opana ER
FDA asked for removal on 8 June 2017; Endo agreed on 6 July 2017

How the score breaks down

The overall score is the weighted average of these factors. Scoring rules

  • Serious side effects30% of score

    30 out of 100, Poor

    Slowed breathing can be fatal, most often at the start or after a dose increase. In FDA-required studies of long-term Controlled substanceA medicine or drug that the law restricts because it can be misused or cause dependence. Countries group them into schedules or classes.More in the glossary opioid users, 1% to 6% newly developed addiction within 12 months, and 1.5% to 4% had an overdose within 5 years.

  • Overdose margin20% of score

    12 out of 100, Poor

    Three times the strength of morphine, with immediate- and extended-release tablets sold in the same 5 mg and 10 mg strengths. Liver disease raised exposure 3.7-fold (moderate) and 12.2-fold (one severe case) in a label study.

  • Interactions15% of score

    20 out of 100, Poor

    Benzodiazepines, alcohol, gabapentinoids and other sedatives can stop breathing. Alcohol also raises blood levels; in a label study, 240 mL of 40% alcohol increased peak levels by 70% on average and up to 270%. CYP enzymes play little part.

  • Dependence and misuse15% of score

    10 out of 100, Poor

    Controlled substanceA medicine or drug that the law restricts because it can be misused or cause dependence. Countries group them into schedules or classes.More in the glossary controlled substance with a high potential for misuse, and Class A in the UK. Injection of crushed Opana ER tablets drove the 2015 HIV outbreak in Scott County, Indiana, with 181 cases by November 2015.

  • Regulatory warnings10% of score

    5 out of 100, Poor

    Full opioid Boxed warningThe strongest safety warning the US FDA puts on a medicine's label, printed inside a black border at the top.More in the glossary and REMS. In June 2017 the FDA asked Endo to remove reformulated Opana ER because the public health harm from injection abuse outweighed its benefits; the approval was formally withdrawn in December 2020.

  • Track record10% of score

    78 out of 100, Good

    Approved in the US in 1959 and sold as Opana ER from 2006, but used far less than oxycodone or morphine, so the evidence base is smaller. Its record includes a failed tamper-resistant version.

Is oxymorphone safe?

Oxymorphone is a strong opioid for severe pain that other treatments have not controlled, and it is one of the less forgiving ones. Milligram for milligram it is three times as strong as morphine and twice as strong as oxycodone, and on top of the usual opioid risks of addiction and fatal slowed breathing, its blood levels jump with alcohol, food and liver disease. Its best-known brand, Opana ER, was removed from the US market in 2017 after the FDA asked for it. We score it 24, below oxycodone and hydromorphone (both 26).

Three things that change the dose you actually get

Most opioids have a predictable relationship between the pill and the amount in your blood. Oxymorphone's is unusually easy to disturb.

The liver. Only about 10% of a swallowed dose reaches the blood, because the liver clears most of it on the first pass. When the liver is damaged, that filter fails. In a label study with extended-release tablets, exposure rose 1.6-fold in mild liver impairment, 3.7-fold in moderate impairment and 12.2-fold in the one patient with severe disease. The label rules it out for moderate or severe liver impairment and starts everyone else with liver problems at 5 mg.

Alcohol. Any sedative adds to an opioid's effect on breathing. With oxymorphone, alcohol also pushes up the amount of drug in the blood. Healthy volunteers who took a 40 mg extended-release tablet with 240 mL of 40% alcohol had peak levels 70% higher on average, and up to 270% higher in some people. The mechanism is unknown, which is why the label says to avoid alcohol completely, including medicines that contain it.

Food. In label studies, eating raised peak levels from extended-release tablets by about 50%. Both tablet types are taken on an empty stomach, at least 1 hour before or 2 hours after a meal.

Kidney problems and age matter too. Moderate to severe kidney impairment raised exposure by 57% to 65%, and people over 65 had levels about 40% higher.

Two tablets, the same strengths

Immediate-release oxymorphone comes in 5 mg and 10 mg tablets, taken every 4 to 6 hours. Extended-release tablets, taken every 12 hours, come in 5, 7.5, 10, 15, 20, 30 and 40 mg. The label warns pharmacists and prescribers about this overlap. Getting a 10 mg extended-release tablet where an immediate-release one was meant is a different dose over a different time, and crushing or chewing an extended-release tablet releases it all at once.

FormStarting dose for someone new to opioids (US label)
Immediate-release tablets10 to 20 mg every 4 to 6 hours as needed
Extended-release tablets5 mg every 12 hours
Mild liver or kidney impairmentStart at 5 mg and increase slowly

What happened to Opana ER

Opana ER was approved in June 2006. In December 2011 the FDA approved a new version, meant to resist crushing for snorting or injecting, and Endo took the original off the market. The FDA never let Endo label the new tablet as abuse-deterrent, because the data did not show it would reduce abuse.

What followed was a shift from snorting to injecting. In 2015, Scott County in rural Indiana, a place that normally saw fewer than five HIV diagnoses a year, had 181 new cases between November 2014 and November 2015. 87.8% of those patients said they had injected extended-release oxymorphone, and 92.3% also had hepatitis C. Indiana declared a public health emergency and opened its first syringe programme. Doctors in other states reported people with kidney failure from thrombotic microangiopathy, a clotting disorder, after injecting the dissolved tablets; some needed dialysis.

On 8 June 2017 the FDA asked Endo to withdraw the reformulated Opana ER, saying its benefits might no longer outweigh the public health consequences of abuse. Endo agreed on 6 July. Generic copies of the original formula stayed on sale, because the FDA had ruled in 2013 that the original was not withdrawn for safety reasons.

Who should be careful

Talk to your doctor about extra safeguards, or other options, if you:

  • have any liver or kidney disease
  • drink alcohol, or take a benzodiazepine, sleeping pill, gabapentin or pregabalin
  • have sleep apnoea, asthma or COPD, or are over 65
  • have had problems with alcohol or drugs
  • are pregnant, because long-term use can cause withdrawal in the newborn
  • live with children: one tablet can kill a child

Check whether each new bottle is immediate- or extended-release, and swallow extended-release tablets whole. Signs of overdose are pinpoint pupils, extreme sleepiness and slow or shallow breathing; call 911, give naloxone if you have it and stay with the person. US Poison Help is 1-800-222-1222. A low score does not mean you should stop a medicine you have been prescribed, and stopping suddenly after weeks of use causes withdrawal, so plan any taper with your prescriber.

How we scored it

Regulatory warnings (5) match fentanyl and methadone at the bottom of the scale, because the FDA asked for one of its brands to be removed. Overdose marginHow far a normal dose is from a harmful one. A wide margin means an accidental extra dose is unlikely to cause serious harm.More in the glossary (12) sits between oxycodone and hydromorphone, pulled down by its strength and its sensitivity to liver disease. Interactions (20) are lower than morphine's because alcohol raises blood levels as well as adding sedation. Dependence (10) and serious side effects (30) match the other Controlled substanceA medicine or drug that the law restricts because it can be misused or cause dependence. Countries group them into schedules or classes.More in the glossary opioids, and track record (78) reflects decades on the market but much narrower use.

Questions people ask

Is oxymorphone stronger than oxycodone?

Yes, about twice as strong. The CDC's 2022 guideline counts 1 mg of oral oxymorphone as 3 mg of oral morphine, against 1.5 mg for oxycodone, so 10 mg of oxymorphone does roughly what 20 mg of oxycodone does. Oxymorphone is also one of the substances the body makes from oxycodone, which is why it can show up in urine tests of people taking oxycodone.

Why was Opana ER taken off the market?

Endo reformulated Opana ER in 2011 to make it harder to crush and snort. Instead, abuse shifted to injection, which was linked to an HIV and hepatitis C outbreak in Indiana and to a rare blood disorder. On 8 June 2017 the FDA asked Endo to remove it, and Endo agreed on 6 July 2017.

Is generic oxymorphone ER still available?

Yes. The FDA ruled in 2013 that the original, non-reformulated Opana ER had not been withdrawn for safety reasons, so generic copies of it stayed on sale. At least one generic extended-release tablet still has a current US label, alongside several immediate-release generics.

Why do you have to take oxymorphone on an empty stomach?

Food raises the amount of drug in the blood. In label studies, peak levels from extended-release tablets were about 50% higher after eating. The label asks for each dose at least 1 hour before or 2 hours after eating. Taking it the same way each time keeps the dose predictable.

Can I drink alcohol while taking oxymorphone?

No. Alcohol adds to the sedation and breathing effects like with any opioid, and with oxymorphone it also raises the amount of drug in the blood. In a study with extended-release tablets, a large drink of spirits raised peak levels by 70% on average and up to 270% in some people.

Sources

  1. 1.Oxymorphone hydrochloride tablets, prescribing information (opens in a new tab) · DailyMed / Hikma, 2026
  2. 2.Oxymorphone hydrochloride extended-release tablets, prescribing information (opens in a new tab) · DailyMed / Amneal, 2026
  3. 3.Endo Pharmaceuticals, Inc.; Withdrawal of Approval of a New Drug Application for OPANA (Oxymorphone Hydrochloride) Extended-Release Tablets (opens in a new tab) · Federal Register (FDA), 2020
  4. 4.Determination That OPANA ER Drug Products Covered by New Drug Application 21-610 Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (opens in a new tab) · Federal Register (FDA), 2013
  5. 5.HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015 (opens in a new tab) · New England Journal of Medicine, 2016
  6. 6.Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone, Indiana, 2015 (opens in a new tab) · CDC MMWR, 2015
  7. 7.Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride (opens in a new tab) · American Journal of Kidney Diseases, 2014
  8. 8.CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (opens in a new tab) · CDC MMWR (Europe PMC), 2022
  9. 9.Controlled Substances – Alphabetical Order (opens in a new tab) · DEA Diversion Control Division, 2026
Spot a mistake?